UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 17, 2026

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-39202

26-2540421

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

101 Lindenwood Drive, Suite 225
Malvern, PA 19355

(Address of Principal Executive Offices, and Zip Code)

(484) 875-3192

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	ANVS	New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 17, 2026, Annovis Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) virtually. At the Annual Meeting, five proposals were submitted to the Company’s stockholders and all matters voted upon were approved with the required votes. The proposals are outlined below and further described in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 30, 2026.

At the Annual Meeting, a total of 21,705,113 shares of the Company’s common stock, or 62.65% of the common stock outstanding as of April 28, 2026, the record date for the Annual Meeting, were represented virtually or by proxy.

The following is a brief description of the final voting results for each of the five proposals submitted at the Annual Meeting on June 17, 2026:

1. Election of Directors

All of the following five nominees were elected to the Company’s Board of Directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.

Nominees:	For	Withold	Broker Non-Vote
Michael Hoffman	8,604,453	550,520	12,550,140
Maria Maccecchini	8,588,620	566,353	12,550,140
Claudine Bruck	8,666,606	488,367	12,550,140
Reid McCarthy	8,591,131	563,842	12,550,140
Mark White	8,204,328	950,645	12,550,140

2. Ratification of the Company’s Independent Auditors

The ratification of the appointment of Ernst & Young LLP was approved by stockholders by the following vote:

For		Against		Abstain
20,634,176		568,155		502,782

3. Amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan

The amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan to increase the number of shares that may be issued under the Plan from 4,000,000 to 5,500,000 and to increase the maximum number of shares that may be awarded in any one year from 400,000 to 600,000 shares, was approved by stockholders by the following vote:

For		Against		Abstain		Broker Non-Vote
8,089,891		899,671		165,409		12,550,142

4. ADVISORY (NON-BINDING) VOTE ON THE COMPENSATION OF THE COMPANY’S NAMED EXECUTIVE OFFICERS

The compensation of the Company’s named executive officers was approved by the stockholders on an advisory (non-binding basis), by the following vote:

Broker Non-Vote

For		Against		Abstain		Broker Non-Vote
8,067,931		901,342		185,701		12,550,139

5. ADVISORY (NON-BINDING) VOTE ON THE PREFERRED FREQUENCY OF FUTURE ADVISORY VOTES ON COMPENSATION OF THE COMPANY’S NAMED EXECUTIVE OFFICERS

“TWO YEARS” as the preferred frequency on the compensation of the Company’s named executive officers was approved by stockholders on an advisory (non-binding basis), by the following vote:

1-Year		2-Years		3-Years		Abstain		Broker Non-Vote
2,526,008		5,390,514		1,086,528		151,922		12,550,141

(d) In light of this vote, and consistent with the recommendation of the Board of Directors, the Company has determined that it will include a stockholder advisory vote on executive compensation in its proxy materials every two years until the next required advisory vote on the frequency of such votes occurs, or until the Board of Directors otherwise determines a different frequency for such votes.

Item 9.01

Financial Statements and Exhibits

Exhibit Number		Description

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANNOVIS BIO, INC.
Date: June 17, 2026
	By:	/s/ Maria Maccecchini
	Name:	Maria Maccecchini
	Title:	Chief Executive Officer

SEC Form 8-K filed by Annovis Bio Inc.